Qi Zhang sees himself as a warrior. In his lab at the University of North Carolina at Chapel Hill, he wages war on genetic diseases such as cancer and heart disease on a battlefield measured with single atoms.
The next chapter in the story of UNC Lineberger Comprehensive Cancer Center begins with a new director, Ned Sharpless, an oncologist with a story to tell.
The cost of insurance co-payments for cutting-edge pharmaceuticals can vary widely from patient to patient. When the patient’s share of prescription costs becomes too high, many patients skip doses or stop taking medication entirely, according to research conducted at the University of North Carolina.
The award, which includes $5,000 in direct research support, recognizes years of service to the CALGB cooperative group by Dr. Muss, who has been a member for more than 30 years.
Screening to detect medical conditions has become standard practice for many diseases, but insufficient attention has been paid to the potential for harm, according to research by a team led by Russell Harris, MD, MPH, of the UNC School of Medicine, UNC Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center.
Adriana S. Beltran, PhD, a research assistant professor in the UNC School of Medicine, found that the protein Engrailed 1 is overexpressed in basal-like carcinomas, and she designed a chain of amino acids to shut down the protein and kill basal-like tumors in the lab.
A Dare County, N.C., wife and mother of three keeps her spunky, positive spirit intact during treatment for thyroid cancer, buoying herself, her family and her medical team on the journey.
This milestone makes the Carolina Breast Cancer Study the largest-ever population-based study of breast cancer in North Carolina and one of the largest in the world.
GlaxoSmithKline drug-discovery competition winners aim to find a new cancer therapy and a novel way to regulate male fertility, projects spearheaded by scientists at the UNC School of Medicine.
Five questions for Yisong Wan, a new Jefferson-Pilot fellow who is uncovering the roles of T cells in disease cures and causes.
A new microbeam emitter developed at the University of North Carolina at Chapel Hill by a team led by UNC Lineberger member Otto Zhou has the potential to bring a promising new form of radiation therapy into clinical use.
Join us at 11 a.m. Eastern time on Friday, Nov. 1, for a discussion of how fathers cope with the loss of their wife or partner, meet the demands of sole parenthood, and manage their children's grief.
The results are the first findings from the North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study.
Five questions for Ronald Chen, a James Woods Young Faculty Award recipient dedicated to bettering treatment for cancer patients.
Patients with poor nutritional status before bladder cancer operation have a higher risk of postoperative complications
New ACS NSQIP® study identifies low blood albumin level as an independent risk factor for surgical-related health problems after radical cystectomy
Walking program reduces joint stiffness in older breast cancer survivors on aromatase inhibitor therapy
After six weeks of walking, the mean joint pain scores among the participants decreased by 10 percent, fatigue decreased by 19 percent, and joint stiffness decreased by 32 percent.
New test uses PAM50 breast cancer gene signature discovered by UNC’s Perou
Physicians experience increased effort, uncertainty in cross-coverage of radiation oncology patients
Radiation oncology physicians who encounter an unfamiliar case when cross-covering for another physician experience higher levels of perceived workload and may also affect performance, according to research conducted at the University of North Carolina.
Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.
Dr. Cynthia Powell of N.C. Children's Hospital and Dr. Jonathan Berg of UNC Lineberger Comprehensive Cancer Center will answer your questions in a live Facebook chat at noon (12 p.m.) Eastern time on Thursday, Sept. 26.